KIDS Healthcare

OrthoPediatrics Corp.

$31.41+3.22%

Price as of close on Nov 3, 2026 · Financials updated Oct 9, 2026

Basics

Sector: Healthcare
Industry: Medical Devices
Country: United States
Market cap: 820.1M USD
Enterprise value: 633.2M USD
Full-time employees: 602

Overall health

Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 0.99 vs a peer median of 0.63), though less than the overall marketbigger price swings (beta 0.99 vs peers 0.63)
About average: risk (debt, liquidity and share-price swings)risk

Ranks #815 of 1,157 healthcare companies (bottom 30%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 14% from December 2022 to August 2026.
OrthoPediatrics had 14% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.OrthoPediatrics had 14% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, OrthoPediatrics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
OrthoPediatrics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $71M in 2020 to $236M in 2025.
OrthoPediatrics's fiscal-year revenue rose in each of the five years to 2025, from $71M to $236M.

StockQuotient Score

41/ 100

Oct 5 41 → Nov 4 41

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-4.8%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-0.9%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-0.2%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield41.9%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

71/100

Moderate

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

12-month revenue up 3.9%

Why

Stronger than most peers on:

▲ 3-yr revenue
▲ Revenue growth

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth22.6%

SEC filings · 3 years to Jun 2026Reported value33% base weight · Z-score 2.00Sector median: 0.0584 · MAD: 0.0840

Revenue growth14.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score 0.86Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

30/100

Weak

3/3 inputs reported · High confidence

Since last quarter: ▲ Stronger

Operating margin rose 3.2 points to -11.9%

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-11.9%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.56Sector median: 0.0706 · MAD: 0.1217

Return on assets-7.8%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.76Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-5.5%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -1.01Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin73.7%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-11.6%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Moderate

Moderate relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Mixed versus peers:

▲ Current ratio
▼ Beta

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta0.99

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.08Sector median: 0.6250 · MAD: 0.3380

Current ratio4.78×

SEC filings · latest balance sheetReported value33% base weight · Z-score 1.58Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.31×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.43Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about OrthoPediatrics

Is OrthoPediatrics getting weaker?: Its latest SEC filing (Aug 5, 2026) got stronger: operating margin rose 3.2 points to -11.9%. Its overall score is unchanged at 41/100 since Oct 28, 2026.
How is OrthoPediatrics valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -4.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -4.8% vs peers 1.5% (weaker than 100% of peers).
Is OrthoPediatrics growing?: Yes, faster than most of its peers. Growth scores 71/100 against 1,393 healthcare peers. 3-year revenue growth 22.6% vs a peer median of 5.8% (stronger than 83% of peers).3-year revenue growth 22.6% vs peers 5.8% (stronger than 83% of peers).
How profitable is OrthoPediatrics?: Less profitable than most of its peers. Profitability scores 30/100 against 1,393 healthcare peers. Operating margin -11.9% vs a peer median of 7.1% (weaker than 76% of peers).Operating margin -11.9% vs peers 7.1% (weaker than 76% of peers).
How risky is OrthoPediatrics?: Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 4.78× vs a peer median of 2.59× (stronger than 72% of peers).Current ratio 4.78× vs peers 2.59× (stronger than 72% of peers). Beta 0.99 vs a peer median of 0.63 (weaker than 71% of peers).Beta 0.99 vs peers 0.63 (weaker than 71% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 5, 2026 · compared with the quarter ended Mar 31, 2026

Got stronger

Operating margin rose 3.2 points to -11.9%

	Previous quarter	Latest quarter	Change
Revenue (12 months)	243.3M USD	252.7M USD	+3.9%
Net income (12 months)	−39.7M USD	−39.7M USD	+0.1%
Operating margin	-15.0%	-11.9%	+3.2 pts
Free cash flow (12 months)	−12.6M USD	−1.8M USD	−85.5%
Debt	106.8M USD	105.9M USD	−0.8%
Cash	12.2M USD	17.0M USD	+39.4%
Shares outstanding	25.7M	26.1M	+1.7%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Medical Devices · 33 companies

Valuations in Medical Devices are near the bottom of their range since 2016.

7% of months since 2016 were valued lower than now.
4% of companies are in the most expensive fifth of their own price-to-sales history.
Over 24 months, company values −8% and earnings +33% (medians): earnings grew faster than prices.
Median price-to-sales is +20% vs the whole market, against a usual +109%.

2016Shaded: most expensive fifth of its range2026

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	74.9%	74.1%	74.8%	72.6%	73.1%	▲ 0.5 pts
Operating margin	-18.4%	-20.8%	-18.0%	-17.1%	-16.6%	▲ 0.5 pts
Net margin	-16.6%	1.0%	-14.1%	-18.5%	-16.8%	▲ 1.7 pts
Return on assets (ROA)	-5.3%	0.3%	-4.8%	-8.0%	-7.8%	▲ 0.2 pts
Return on equity (ROE)	-7.2%	0.3%	-5.6%	-10.7%	-11.4%	▼ 0.8 pts
Free cash flow margin	-21.6%	-26.0%	-29.5%	-20.2%	-6.8%	▲ 13 pts
Current ratio	4.50×	7.34×	5.44×	6.98×	5.55×	▼ 21%
Quick ratio	2.56×	4.81×	2.90×	3.54×	2.65×	▼ 25%
Debt to equity	0.00×	0.00×	0.03×	0.22×	0.31×	▲ 40%
Interest coverage	-321.86×	-10.48×	-135.11×	-13.36×	-6.54×	▲ 51%

KIDS price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 0.99 vs a peer median of 0.63), though less than the overall marketbigger price swings (beta 0.99 vs peers 0.63)

About average: risk (debt, liquidity and share-price swings)risk

Ranks #815 of 1,157 healthcare companies (bottom 30%)

See how it ranks against its peers

Worth knowing

Shareholders being diluted. Shares outstanding up 14% from December 2022 to August 2026.

OrthoPediatrics had 14% more shares at August 2026 than at December 2022, mostly from issuing stock (for pay, acquisitions or fundraising). Each existing share now owns a smaller slice of the business.OrthoPediatrics had 14% more shares at August 2026 than at December 2022, mostly from issuing stock. Each existing share now owns a smaller slice of the business.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, OrthoPediatrics looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

OrthoPediatrics reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Annual revenue rose 5 years in a row. Fiscal-year revenue rose from $71M in 2020 to $236M in 2025.

OrthoPediatrics's fiscal-year revenue rose in each of the five years to 2025, from $71M to $236M.

Questions investors ask about OrthoPediatrics

Is OrthoPediatrics getting weaker?

Its latest SEC filing (Aug 5, 2026) got stronger: operating margin rose 3.2 points to -11.9%. Its overall score is unchanged at 41/100 since Oct 28, 2026.

How is OrthoPediatrics valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -4.8% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -4.8% vs peers 1.5% (weaker than 100% of peers).

Is OrthoPediatrics growing?

Yes, faster than most of its peers. Growth scores 71/100 against 1,393 healthcare peers. 3-year revenue growth 22.6% vs a peer median of 5.8% (stronger than 83% of peers).3-year revenue growth 22.6% vs peers 5.8% (stronger than 83% of peers).

How profitable is OrthoPediatrics?

Less profitable than most of its peers. Profitability scores 30/100 against 1,393 healthcare peers. Operating margin -11.9% vs a peer median of 7.1% (weaker than 76% of peers).Operating margin -11.9% vs peers 7.1% (weaker than 76% of peers).

How risky is OrthoPediatrics?

Moderate risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 4.78× vs a peer median of 2.59× (stronger than 72% of peers).Current ratio 4.78× vs peers 2.59× (stronger than 72% of peers). Beta 0.99 vs a peer median of 0.63 (weaker than 71% of peers).Beta 0.99 vs peers 0.63 (weaker than 71% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

243.3M USD

252.7M USD

+3.9%

Net income (12 months)

−39.7M USD

−39.7M USD

+0.1%

Operating margin

-15.0%

-11.9%

+3.2 pts

Free cash flow (12 months)

−12.6M USD

−1.8M USD

−85.5%

Debt

106.8M USD

105.9M USD

−0.8%

Cash

12.2M USD

17.0M USD

+39.4%

Shares outstanding

25.7M

26.1M

+1.7%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

74.9%

74.1%

74.8%

72.6%

73.1%

▲ 0.5 pts

Operating margin

-18.4%

-20.8%

-18.0%

-17.1%

-16.6%

▲ 0.5 pts

Net margin

-16.6%

1.0%

-14.1%

-18.5%

-16.8%

▲ 1.7 pts

Return on assets (ROA)

-5.3%

0.3%

-4.8%

-8.0%

-7.8%

▲ 0.2 pts

Return on equity (ROE)

-7.2%

0.3%

-5.6%

-10.7%

-11.4%

▼ 0.8 pts

Free cash flow margin

-21.6%

-26.0%

-29.5%

-20.2%

-6.8%

▲ 13 pts

Current ratio

4.50×

7.34×

5.44×

6.98×

5.55×

▼ 21%

Quick ratio

2.56×

4.81×

2.90×

3.54×

2.65×

▼ 25%

Debt to equity

0.00×

0.03×

0.22×

0.31×

▲ 40%

Interest coverage

-321.86×

-10.48×

-135.11×

-13.36×

-6.54×

▲ 51%